MED18 is a component of the Mediator complex head module, a conserved coactivator essential for regulated transcription of RNA polymerase II-dependent genes 1. The Mediator complex functions as a bridge conveying information from gene-specific regulatory proteins to basal transcription machinery, with MED18 contributing to preinitiation complex assembly and interaction with RNA polymerase II 1. MED18 contains intrinsically disordered regions that facilitate structural transitions and protein-protein interactions critical for Mediator's malleable architecture 2. Functionally, MED18 exhibits a negative regulatory role in transcription. siRNA-mediated depletion of human MED18 augmented transcription at target promoters including RAM and DMT1 genes, indicating MED18-mediated transcriptional repression independent of histone deacetylase activity 3. This repression involves interaction with the CDK/cyclin module, suggesting a novel mechanism where MED18 coordinates with CDK8 for transcriptional regulation 3. Clinically, MED18 dysregulation associates with multiple malignancies. In gastric cancer, lncRNA SNHG3 epigenetically suppresses MED18 expression through EZH2-mediated methylation, with MED18 loss driving tumor progression, proliferation, and metastasis 4. In bladder cancer, lncRNA UCA1α downregulates MED18 expression, correlating with increased cell proliferation 5. Additionally, MED18 copy number alterations occur in MED12-negative uterine leiomyomas, potentially affecting Mediator architecture 6, and aberrant MED18 splicing contributes to biallelic TP53 inactivation in multiple myeloma 7.